Welcome to our Land of Opportunity
Neuland is the dedicated 100%
API provider
To all our potential customers please know
that nearly all collaborators on our journey
remain customers to this day
Worldwide compliance and our no compromise
quality standards give real reassurance to our
global customer base
Neuland is a no-compromise, API manufacturing service provider, offering worldwide compliant manufacturing facilities to its customers that it guarantees not to compete with in finished product.
The Dedicated 100% API Provider
Our core business and operational expertise has been as a service provider in the manufacturing of Generic Drug Substances. Neuland is the preferred and reliable source of supply for several leading pharmaceutical companies worldwide.
Our Custom Manufacturing Solutions (CMS) division has proven expertise in manufacturing at varied scales, a deep understanding of complex chemistry and manufacturing facilities compliant with the guidelines of the leading regulatory authorities.
Neuland’s peptide synthesis services include production of peptides from milligrams to multi-kilogram scale by standard sequential chemical peptide synthesis and segment condensation strategies. We have developed a novel Prep-RP-HPLC method that uses a quaternary ammonium salt as an additional/surrogate stationary phase.
Neuland is at the forefront of facilitating and accelerating drug development and cGMP manufacturing of APIs. The Company’s technical and scientific teams provide reliable solutions and services to the global pharmaceutical industry.
Come and meet us next at CPhI Worldwide in Frankfurt on the 24th - 26th October 2017, Booth No: 8.0H40 Contact us today to arrange a meeting and we will look forward to seeing you there.
Defining the Contract Pharma Provider Relationship
Posted on June 18, 2017 by Saharsh Davuluri
I read an article at Pharmaceutical Manufacturing earlier this year (Inking the Deal: Mastering the art of lasting outsourcing relationships in the pharmaceutical industry) on the nature of contract pharma…
